Precigen, Inc. Regains Compliance with Nasdaq Listing Rules

Precigen, Inc. (NASDAQ: PGEN) recently announced that it has successfully regained compliance with the Nasdaq Listing Rule 5450(a)(1) after its common stock consistently traded at or above $1.00 per share for the last 10 consecutive business days. The company had received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on November 1, 2024, indicating that Precigen was not in compliance with the Bid Price Rule due to its stock price being below $1.00 for 30 consecutive business days.

Following the initial non-compliance notification, Precigen was given a 180-day grace period until April 30, 2025, to rectify the situation. On January 16, 2025, Precigen received written confirmation from Nasdaq that its common stock had exceeded the $1.00 per share threshold over the specified period. As a result, the issue of non-compliance with the Bid Price Rule has been resolved.

Donald P. Lehr, Chief Legal Officer of Precigen, expressed the company’s commitment to maintaining compliance with all applicable listing requirements and ensuring transparency for investors. With the successful regaining of compliance, Precigen looks forward to focusing on its strategic objectives and continuing to drive shareholder value.

Investors and stakeholders of Precigen can now be assured that the company has addressed the concern raised by Nasdaq and is in good standing with the exchange’s listing regulations. This development marks a positive step for Precigen as it strives to enhance its market position and deliver long-term value to its shareholders.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Precigen’s 8K filing here.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.